ESMO Symposium on Signalling Pathways in Cancer 2015 – Targeting the MAPK pathway: From RAS to MEK

Barcelona, Spain - 13 Mar - 14 Mar 2015

After an outstanding 2nd edition in 2014, we would proudly like to present the 3rd ESMO Symposium on Signalling Pathways in Cancer. The main goal of this symposium is to provide an educational, comprehensive update to oncology professionals regarding the current scientific developments that stand behind molecular pathways leading to more personalised approach in the treatment of cancer.

The 2015 Symposium will concentrate on targeting the MAPK pathway: from RAS to MEK. The programme will cover preclinical data and genetics relevant for the understanding of the functional mechanisms in the RAS/ERK/MEK pathway, regulation of MAPK signalling, the rationale and strategies to inhibiting the pathway, biomarkers, mechanisms of resistance, as well as how to overcome it, and some important interactions with other pathways.

Updates will also be provided on different aspects important for rational clinical development of novel RAS/ERK/MEK inhibitors, as well as an exploration – from a clinical perspective- of recent achievements and data from ongoing research and clinical trials, targeting the axes of the MAPK pathway across a wide range of solid tumours.

We are confident that attendees will benefit from this meeting and we look forward to seeing you again in further editions.  

Chairs:

Solange Peters, Switzerland and Giampaolo Tortora, Italy